Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Reneo Pharmaceuticals (NASDAQ: RPHM) announced its management team will participate in three key healthcare conferences this September. The conferences are the Baird Global Healthcare Conference on September 13-14 in New York, the 11th Annual SVB Securities Healthcare Summit from September 21-23 in California, and the Ladenburg Thalmann Annual Healthcare Conference on September 29 in New York. Links to the presentations will be available on the company’s website. Reneo focuses on therapies for rare genetic mitochondrial diseases, with its lead candidate, REN001, targeting mitochondrial function.

IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the following conferences in September, as detailed below:

Baird Global Healthcare Conference (September 13-14, 2022)
Location: InterContinental New York Barclay, Morgan Suite, Mezzanine Level
Presentation: Tuesday, September 13, 2022, 10:50AM ET (Session IV)

11^th Annual SVB Securities Healthcare Summit (September 21-23, 2022)
Location: Rosewood Miramar Beach, Montecito, California

Ladenburg Thalmann Annual Healthcare Conference (September 29, 2022)
Location: Sofitel Hotel, New York, NY, Track 3 – Montmarte
Fireside Chat: Thursday, September 29, 2022, 11:00 AM ET

Links to the presentations will be posted on the Investors section of the Reneo Pharmaceuticals corporate website, under Events and Presentations.

About Reneo Pharmaceuticals

Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
dspangler@reneopharma.com

FAQ

What conferences is Reneo Pharmaceuticals attending in September 2022?

Reneo Pharmaceuticals will attend the Baird Global Healthcare Conference, the 11th Annual SVB Securities Healthcare Summit, and the Ladenburg Thalmann Annual Healthcare Conference.

When and where is the Baird Global Healthcare Conference?

The Baird Global Healthcare Conference is on September 13-14, 2022, at the InterContinental New York Barclay.

What is the schedule for Reneo Pharmaceuticals at the Baird Conference?

Reneo Pharmaceuticals will present on September 13, 2022, at 10:50 AM ET.

Where will the 11th Annual SVB Securities Healthcare Summit be held?

The 11th Annual SVB Securities Healthcare Summit will take place at Rosewood Miramar Beach in Montecito, California, from September 21-23, 2022.

What can you tell me about Reneo Pharmaceuticals' lead product candidate?

Reneo's lead product candidate, REN001, is designed to enhance mitochondrial function and fatty acid oxidation in patients with rare genetic mitochondrial diseases.

When is the Ladenburg Thalmann Annual Healthcare Conference?

The Ladenburg Thalmann Annual Healthcare Conference is set for September 29, 2022.

What is the focus of Reneo Pharmaceuticals?

Reneo Pharmaceuticals focuses on developing therapies for patients with rare genetic mitochondrial diseases.